5 DAANCE Practice Questions That Trip Up Most Candidates
Real clinical DAANCE-style questions with the wrong-answer traps explained. See which details separate a first-try pass from a retake.
April 19, 2026 · Garry Mills
The DAANCE does not reward rote memorization. It rewards clinical reasoning. The difference matters: a question that asks "what is the max dose of lidocaine with epi?" tests recall. A question that says "you have a 25 kg child, 2% lidocaine with epi, the procedure is starting — how many cartridges can you safely use?" tests whether you can apply that knowledge under conditions that actually look like your job.
That distinction is exactly where most candidates lose points. They know the drug. They do not know how to use the number they memorized in the context the question is presenting. The five questions below are built around the clinical traps the exam returns to repeatedly — weight-based dosing, earliest signs of emergencies, first-line versus adjunct drugs, reversal agent pharmacokinetics, and discharge criteria.
Work through each question before reading the explanation. If you get it right, read the distractor analysis anyway — knowing why the wrong answers are wrong is how you generalize to questions you haven't seen before.
Question 1: Pediatric Lidocaine Dose Calculation
Scenario: A 25 kg, 7-year-old patient is scheduled for extraction of two primary molars. The dentist plans to use 2% lidocaine with epinephrine 1:100,000. The child is otherwise healthy with no relevant medical history. What is the maximum safe volume, in cartridges, that can be administered?
A. 3.5 cartridges
B. 4.9 cartridges
C. 6.3 cartridges
D. 8.9 cartridges
Correct answer: B — 4.9 cartridges
Explanation:
The calculation:
- Max dose of lidocaine with epi = 7 mg/kg
- Patient weight = 25 kg
- 25 kg × 7 mg/kg = 175 mg maximum
- Each 1.8 mL dental cartridge of 2% lidocaine contains: 2% = 20 mg/mL × 1.8 mL = 36 mg per cartridge
- 175 mg ÷ 36 mg/cartridge = 4.86 cartridges → round down to 4.9 (or safely, 4 full cartridges)
Why the wrong answers fail:
- A (3.5 cartridges): This is the calculation using 4.4 mg/kg — the max dose for lidocaine plain (without epi). The vasoconstrictor extends the safe ceiling to 7 mg/kg. Confusing these two is the single most common error on this topic.
- C (6.3 cartridges): This reflects applying adult weight-based dosing (the absolute cap of 500 mg) without accounting for the child's actual weight. The 500 mg cap is an adult ceiling, not a pediatric override.
- D (8.9 cartridges): No clinical basis. Likely results from omitting weight-based calculation entirely and applying a flat dose guideline. In a 25 kg child, 8.9 cartridges would deliver over 320 mg — nearly double the safe limit.
Clinical takeaway: Pediatric local anesthetic dosing is always weight-based without exception. The absolute adult caps (300 mg plain, 500 mg with epi) do not apply to children — they function as ceiling floors for adults, not pediatric targets. For every pediatric question: multiply weight × max mg/kg, divide by mg per cartridge. Do not skip steps.
Question 2: First Sign of Malignant Hyperthermia
Scenario: A 34-year-old patient with no significant medical history is 20 minutes into general anesthesia with a volatile inhalational agent. The circulating dental anesthesia assistant notices the ETCO2 reading has climbed from 38 mmHg to 58 mmHg over the past 10 minutes. Heart rate has increased from 72 to 104 bpm. The patient's skin temperature feels normal to the touch. What is the FIRST action to take?
A. Apply active cooling measures — ice packs to axillae and groin
B. Check the patient's core temperature with a rectal thermometer
C. Discontinue the triggering anesthetic agent and call for dantrolene
D. Administer acetaminophen IV to address the developing hyperthermia
Correct answer: C — Discontinue the triggering anesthetic agent and call for dantrolene
Explanation:
Malignant hyperthermia (MH) is a pharmacogenetic disorder triggered by volatile inhalational anesthetics (halothane, sevoflurane, desflurane, isoflurane) and succinylcholine. The skeletal muscle crisis causes a massive increase in metabolic rate — CO2 production surges before body temperature rises measurably.
Rising ETCO2 is the earliest reliable sign of MH. By the time temperature is elevated on exam, the crisis is already advanced. In this scenario, the ETCO2 rise plus tachycardia in the context of a volatile anesthetic is malignant hyperthermia until proven otherwise.
The treatment sequence:
- Stop the trigger — discontinue the volatile agent immediately
- Call for dantrolene — 2.5 mg/kg IV, repeat every 5 minutes up to 10 mg/kg
- Hyperventilate with 100% O2
- Active cooling (cold saline, ice packs, cooling blankets)
- Treat metabolic acidosis and hyperkalemia
- Transfer to ED
Why the wrong answers fail:
- A (active cooling first): Cooling is part of the treatment protocol, but it is not step one. If you cool without stopping the trigger, the crisis continues. Removing the cause takes absolute priority.
- B (check temperature): This is the most commonly chosen wrong answer. Candidates who have memorized "fever = MH" assume temperature verification is the first step. It is not. ETCO2 rises first. Waiting to confirm fever delays dantrolene administration by critical minutes.
- D (acetaminophen IV): This treats the symptom, not the cause, and has no role in MH management. MH hyperthermia is not mediated by prostaglandins — it is caused by uncontrolled calcium release in skeletal muscle. Antipyretics are ineffective.
Clinical takeaway: Rising ETCO2 + tachycardia during volatile anesthetic = MH until proven otherwise. Temperature is a late sign. Stop the trigger and get dantrolene. This question tests whether you know the timeline of MH presentation — not just that dantrolene is the drug.
Question 3: First-Line Treatment for Anaphylaxis
Scenario: A 29-year-old patient receives amoxicillin 500 mg orally as prophylaxis prior to a dental procedure. Approximately 12 minutes later, the patient reports throat tightness and itching. On assessment: generalized urticaria on the arms and chest, audible wheezing bilaterally, blood pressure 84/50 mmHg (baseline 122/78). The patient is anxious and restless. What is the FIRST drug you administer?
A. Diphenhydramine 50 mg IM
B. Hydrocortisone 200 mg IV
C. Epinephrine 0.3 mg IM into the anterolateral thigh
D. Albuterol 2.5 mg via nebulizer
Correct answer: C — Epinephrine 0.3 mg IM into the anterolateral thigh
Explanation:
This patient has anaphylaxis. Three systems are involved: skin (urticaria), respiratory (wheezing), and cardiovascular (hypotension). That triad meets the clinical criteria without ambiguity.
Epinephrine is always the first-line drug for anaphylaxis. It is not a drug you give after antihistamines fail. It is not an adjunct. It is the intervention that prevents death by reversing bronchospasm (beta-2), counteracting vasodilation and hypotension (alpha-1), and reducing mediator release from mast cells.
Dosing: 0.3–0.5 mg (1:1,000 concentration) IM into the anterolateral thigh (vastus lateralis). The thigh is preferred over the deltoid because absorption is faster — higher muscle mass and vascularity.
After epinephrine:
- Call 911
- Lay patient supine with legs elevated (unless respiratory distress requires upright positioning)
- Repeat epinephrine every 5–15 minutes if no improvement
- Diphenhydramine and hydrocortisone are adjuncts — given after epinephrine, not instead of it
Why the wrong answers fail:
- A (diphenhydramine first): The most dangerous wrong answer. Diphenhydramine blocks histamine receptors and helps with urticaria, but it does not reverse bronchospasm or hypotension. Giving antihistamines while withholding epinephrine during anaphylaxis has resulted in preventable deaths. Diphenhydramine is an adjunct — it comes after epinephrine.
- B (hydrocortisone first): Steroids take 4–6 hours to produce meaningful anti-inflammatory effect. They help prevent biphasic reactions but have no role in initial resuscitation. No immediate benefit to a patient with active bronchospasm and hypotension.
- D (albuterol first): Addresses bronchospasm but does not reverse hypotension or urticaria. In anaphylaxis the mechanism is systemic — albuterol treats one piece. Epinephrine treats all of it simultaneously.
Clinical takeaway: Epinephrine → IM → anterolateral thigh → first. Every time. If you hesitate on anaphylaxis first-line drug, you will hesitate in the operatory. The DAANCE tests this because the wrong answer (diphenhydramine) is intuitive to people who think of allergic reactions as "antihistamine problems." Anaphylaxis is not. See the DAANCE pharmacology cheat sheet for the full emergency drug reference table.
Question 4: Flumazenil Reversal and Re-Sedation Monitoring
Scenario: A 52-year-old patient received midazolam 5 mg IV for conscious sedation during a lengthy extraction. Toward procedure end, the patient's respiratory rate drops to 7 breaths/minute and they are not arousable to verbal stimulation. Flumazenil 0.2 mg IV is administered with good response — the patient becomes alert, verbal, and respiratory rate returns to 14/min. How long should this patient be monitored before discharge is considered?
A. 30 minutes — flumazenil reversal is complete and the patient is now alert
B. 45 minutes — standard post-sedation observation window
C. At least 2 hours — flumazenil has a shorter half-life than midazolam
D. 60 minutes — the patient may be discharged once Aldrete score ≥8
Correct answer: C — At least 2 hours
Explanation:
Flumazenil reverses benzodiazepine sedation by competitive antagonism at the GABA-A receptor. The problem is pharmacokinetic: flumazenil's half-life is approximately 40–80 minutes. Midazolam's half-life is 2–6 hours. When flumazenil wears off, the unmetabolized midazolam still present in the patient's system can reassert its sedative effect — a phenomenon called re-sedation.
This is not a theoretical concern. A patient who receives flumazenil, appears alert, and is discharged at 30–45 minutes can become sedated again in the car, at home, or on stairs.
The monitoring window after flumazenil administration is at least 2 hours — long enough to outlast flumazenil's duration of effect and confirm the patient is not re-sedating as the antagonist clears.
Additional clinical points:
- Flumazenil max dose = 1 mg total (initial 0.2 mg, may repeat 0.2 mg doses every 1 minute)
- Does NOT reverse respiratory depression from opioids — that requires naloxone
- Does NOT reverse propofol sedation — no reversal agent exists for propofol
Why the wrong answers fail:
- A (30 minutes): Less than the lower bound of flumazenil's half-life. The patient may appear recovered at 30 minutes and re-sedate as flumazenil clears. This reflects a misunderstanding of reversal — it means temporary antagonism, not elimination of the benzodiazepine.
- B (45 minutes): Still insufficient. The "standard observation window" framing sounds reasonable but ignores re-sedation pharmacokinetics.
- D (60 minutes, Aldrete ≥8): Two errors. Sixty minutes is below the 2-hour minimum monitoring window, and the Aldrete discharge threshold is ≥9, not ≥8.
Clinical takeaway: Reversal does not mean safe to go. It means the clock resets. Flumazenil is a loan of clarity — the drug it reversed is still in the patient's system. Monitor for at least 2 hours and watch for signs of returning sedation: decreased responsiveness, slowed speech, drooping eyelids, declining oxygen saturation.
Question 5: Aldrete Score and Discharge Threshold
Scenario: A 45-year-old patient has completed a 90-minute procedure under IV conscious sedation and is recovering in the post-anesthesia care area. The anesthesia assistant performs an Aldrete assessment 45 minutes post-procedure. Results: Activity 2, Respiration 2, Circulation 2, Consciousness 1, O2 Saturation 1. The patient is asking when they can go home. Can this patient be discharged to phase II recovery (ambulatory discharge)?
A. Yes — a score of 8 meets the clinical threshold for phase II discharge
B. Yes — all five categories have been assessed and the patient is responsive
C. No — the patient requires an Aldrete score of ≥9 before phase II discharge
D. No — patients who received IV sedation must always be held for a minimum of 4 hours regardless of Aldrete score
Correct answer: C — No, the patient requires an Aldrete score of ≥9
Explanation:
The Aldrete Score (Modified Aldrete Scoring System) is the standard tool for evaluating post-anesthesia recovery readiness. Five categories, each scored 0–2:
| Category | Score 2 | Score 1 | Score 0 | |----------|---------|---------|---------| | Activity | Moves all 4 extremities | Moves 2 extremities | No movement | | Respiration | Breathes deeply, coughs freely | Dyspnea or limited breathing | Apnea | | Circulation | BP ±20% of pre-op baseline | BP ±20–49% of baseline | BP ±50%+ of baseline | | Consciousness | Fully awake | Arousable on call | Not responding | | O2 Saturation | SpO2 >92% on room air | Needs supplemental O2 | SpO2 <90% even with O2 |
Maximum score: 10. Minimum for phase II discharge eligibility: ≥9.
This patient scored 8/10 (Activity 2 + Respiration 2 + Circulation 2 + Consciousness 1 + O2 Sat 1 = 8). An 8 is not sufficient. The patient is not yet eligible for phase II discharge regardless of how alert they seem or how motivated they are to leave.
The consciousness score of 1 means the patient is arousable but not fully awake — a meaningful clinical distinction. The O2 saturation score of 1 means they are not maintaining >92% on room air, requiring supplemental oxygen. Either of those findings alone warrants continued monitoring.
Why the wrong answers fail:
- A (score of 8 meets threshold): This is the central misconception the question is testing. 8 is one point below the threshold. The threshold is 9, not 8. Candidates who recall "high Aldrete score = okay to discharge" without remembering the exact cutoff choose A.
- B (all categories assessed + patient responsive): Assessment completeness and patient responsiveness are not discharge criteria. The scoring system exists precisely to standardize this judgment — the score is what matters, not the fact that the form was filled out.
- D (mandatory 4-hour hold for IV sedation): No universal 4-hour minimum exists in standard Aldrete-based discharge protocols. Hold duration is determined by clinical status and scoring, not an arbitrary time floor. This distractor sounds authoritative but reflects a conflation with different institutional protocols.
Clinical takeaway: Aldrete ≥9 to leave phase I recovery. Aldrete = 10 is ideal but not required. An 8 means something is still off — identify the category with the lower score, address it, reassess. Do not discharge a patient at 8 because they are asking to leave or because the operatory needs the room.
How to Use These Questions
Five questions is a sample. The DAANCE has 120 scored items, and the clinical traps above repeat in different packaging throughout the exam. Pediatric dosing questions will use different drugs and different weights. MH questions will change the trigger agent or the setting. Anaphylaxis questions will vary the allergen or the vitals. The mechanism of the trap stays the same.
What you need is not more exposure to these five scenarios — you need a system that shows you every variation, tracks which categories you miss, and prioritizes those for review. Retaking the same practice questions you've already seen tells you nothing useful.
CertCleared's diagnostic quiz maps your answers to DAANCE content domains and identifies your weakest areas before you've wasted study time on content you already know. Take it before you build your study schedule — you'll spend your remaining time on the questions that are actually going to cost you points.